Gilead's Shares Fall 0.32% as $520M Volume Dips 50.66% to 170th Market Rank Amid Mixed Earnings Report

Gilead Sciences (GILD) fell 0.32% on August 18, 2025, with a trading volume of $0.52 billion, marking a 50.66% decline from the previous day’s volume and ranking 170th in market activity. The stock’s performance followed a mixed earnings report and strategic updates from the biopharmaceutical giant.

Gilead reported second-quarter revenues of $7.1 billion, exceeding expectations, driven by strong sales in its HIV portfolio. Biktarvy and Descovy, key HIV treatments, saw year-over-year growth of 9% and 35%, respectively, bolstering confidence in the franchise’s resilience. The company raised full-year guidance, citing robust demand for HIV therapies and the recent FDA approval of Yeztugo, a long-acting PrEP drug, which aims to address adherence challenges in prevention markets.

However, challenges emerged in other segments. The Cell Therapy franchise, including Yescarta and Tecartus, faced declining sales due to competitive pressures in the U.S. and Europe. Additionally, the Liver Disease portfolio reported a 4% decline, primarily from reduced hepatitis C virus (HCV) sales amid pricing adjustments linked to Medicare Part D redesign. Despite these headwinds, demand for Livdelzi and other HBV treatments partially offset the decline.

Gilead’s financial position remains strong, with $7.1 billion in cash and equivalents as of June 30, 2025. The company also maintained a 2.67% dividend yield, supported by $994 million in quarterly dividend payments and $527 million in share repurchases. Analysts noted a modest increase in 2025 earnings estimates, reflecting cautious optimism about the company’s innovation pipeline and strategic collaborations, such as its partnership with Merck to develop HIV treatments.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day generated a cumulative return of 23.4% from 2022 to the present, yielding $2,340 in profit. While the approach delivered positive results, the returns were described as modest given market volatility and the conservative holding period.